×

You are using a browser that is no longer supported for this website.
Please use the latest version of Chrome, Firefox, Edge or Safari.

EXCOR® Pediatric

With our products we support patients with heart failure worldwide - from newborns to adults.

EXCOR® Pediatric

The ventricular assist device for young patients

EXCOR® Pediatric is a paracorporeal, pulsatile ventricular assist device, also called VAD for short. Paracorporeal means that the blood pumps are located outside the body and are connected with the heart and blood vessels via cannulae. The system can be used for the mechanical support of one ventricle (left-sided / LVAD or right-sided / RVAD) or of both ventricles (both sides / BVAD).

The System

The only system worldwide designed for children, toddlers and babies

Berlin Heart has especially developed the EXCOR® Pediatric VAD for use in children, small children, and even infants. Thanks to the variety of blood pumps and cannulae, we can supply patients of different sizes in a more customized manner.Pediatric VAD for use in children, small children, and even infants. Thanks to the variety of blood pumps and cannulae, we can supply patients of different sizes in a more customized manner.

Functionality

The central element of the EXCOR® ventricular assist device is the blood pump. It consists of a blood chamber and an air chamber, which are separated by a triple-layer membrane. A pneumatic driving unit alternately pumps air, through a tube, into and out of the blood pump's air chamber. As a result, the membrane moves in a pulsating manner. This causes the blood to be pumped through cannulae out of the body, into the blood-carrying side of the pump, and back into the body. Similarly to the heart, the EXCOR® blood pump possesses valves. These ensure that the blood flows in only one direction. Here, the pump rate can be adjusted to the individual needs of the patient.                                  

Implantation

The EXCOR® is implanted using standardized surgical techniques and a cardiopulmonary bypass machine. The CPB machine takes over the circulation and oxygenation of the blood while the EXCOR® cannulae are connected to the heart and blood vessels. After the cannulae have been tunneled through the skin, the surgeon connects the cannulae to the EXCOR® blood pump. The VAD team adjusts the pump rate and the pump pressures via the Ikus stationary driving unit. This ensures an optimal blood pump function. At the same time, the patient is gradually weaned from the CPB machine and the EXCOR® VAD takes over the total pump output.

The hospital stay

After implantation, the patient receives care in the intensive care unit. Experienced cardiologists care for the young patients and regularly conduct routine lab tests and ultrasound examinations. Depending on their initial condition, it may take a few weeks for the patient to recover. Physicians regularly check the transcutaneous exit sites of the cannulae, clean them, and place sterile wound dressings in order to promote a fast healing process. The function of the ventricular assist device is continuously monitored. In order to avoid the formation of thrombi, the young patient takes anticoagulants from that point on.

Everyday life with the EXCOR® Pediatric

On the pediatric ward the parents of young patients can – depending on the individual circumstances – take on an active role and help care for their children. The transcutaneous (skin-penetrating) exit sites of the cannulae are regularly cleaned and dressed in sterile bandages to promote a fast healing process. If the child is healthy enough, it can play in the playroom and even receive school instruction at the hospital.

The VAD team and the nurses will train the patient's caregivers on the use of the EXCOR® system, monitoring of the pump and the Ikus driving unit. The EXCOR® system settings are selected so that it can supply the young patient with an adequate total pump output. In this manner, rehabilitation and physiotherapy can already start, in theory, prior to the heart transplantation.

In order to accelerate the recovery process, movement is also important. This applies especially to babies and toddlers, who learn to crawl and walk in the hospital. We place great value on our small patients being supported in their development, even during EXCOR® therapy.

 

The outpatient care of young patients

If certain conditions are fulfilled, young patients can use the Excor® mobil driving system. The Excor® mobil allows patients to return to normal everyday life more quickly. Before discharge, the VAD team explains to patients and their families such things as:

  • what to watch for when changing dressings and caring for wounds
  • how to perform a pump control and what needs to be watched for
  • how to control the operating time of the main battery
  • how to replace batteries, and
  • how to properly react to VAD notices

Note: The therapy descriptions presented here are only illustrative and may vary from patient to patient. If you have questions regarding your individual condition and therapy options, please talk to your treating physician.

 

Patient Video

Share your Story

Lorena from Maceió, Brasilien

EXCOR® Pediatric

Only six days after her birth in Maceió, the capital of the Brazilian state of Alagoas, Lorena’s medical history takes its course....

Elena from Germany

EXCOR® Pediatric

"We are so blessed that Elena's heart recovered."

– David Y., Elena's father

 

Juniper from the USA

EXCOR® Pediatric

Two weeks after Juniper’s birth, her parents took her to the doctor for her first check-up. Assuming they had a healthy baby,...

The access to some or all shown products may be restricted due to country-specific regulatory approvals. IKUS and EXCOR® Active are/is intended for professional healthcare facility environments only.

The use of EXCOR® VAD for adults, RVAD-support, EXCOR® Blood pumps with bileaflet valves, EXCOR® Venous Cannula, EXCOR® Arterial Cannula for Graft, Caddy quattro kit as well as Excor mobile is not FDA approved. EXCOR® Active is an investigational device approved for pediatric use in a clinical study under IDE# G200252 approved by the FDA.